blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2993180

EP2993180 - NOVEL JNK INHIBITOR MOLECULES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.11.2020
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  13.12.2019
FormerGrant of patent is intended
Status updated on  04.12.2019
FormerExamination is in progress
Status updated on  19.11.2019
FormerGrant of patent is intended
Status updated on  17.06.2019
FormerExamination is in progress
Status updated on  15.06.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Xigen Inflammation Ltd.
Arch. Makariou III
195 Neocleous House
3030 Limassol / CY
[2016/10]
Inventor(s)01 / Bonny, Christophe
En vernaules
1580 Avenches / CH
 [2016/10]
Representative(s)Weickmann & Weickmann PartmbB
Postfach 860 820
81635 München / DE
[N/P]
Former [2016/10]Graf von Stosch, Andreas, et al
Graf von Stosch
Patentanwaltsgesellschaft mbH
Prinzregentenstraße 22
80538 München / DE
Application number, filing date15002211.921.06.2011
[2016/10]
Priority number, dateWO2010EP0372921.06.2010         Original published format: PCT/EP2010/003729
[2016/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2993180
Date:09.03.2016
Language:EN
[2016/10]
Type: B1 Patent specification 
No.:EP2993180
Date:15.01.2020
Language:EN
[2020/03]
Search report(s)(Supplementary) European search report - dispatched on:EP27.11.2015
ClassificationIPC:C07K7/06, C07K14/47, G01N33/53
[2016/10]
CPC:
A61P43/00 (EP); C07K7/06 (EP,CN,KR,US); C07K7/08 (CN,US);
A61K39/00 (EP,CN,KR,US); C07K14/001 (US); C07K14/47 (KR);
C07K14/4702 (EP,CN,US); C07K16/18 (CN); C07K16/44 (US);
G01N33/53 (KR); A61K2039/552 (US); C07K2317/14 (US);
C07K2317/34 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/10]
TitleGerman:NEUARTIGE JNK-HEMMERMOLEKÜLE[2016/10]
English:NOVEL JNK INHIBITOR MOLECULES[2016/10]
French:NOUVELLES MOLÉCULES D'INHIBITEUR JNK[2016/10]
Examination procedure27.07.2015Examination requested  [2016/10]
28.07.2016Amendment by applicant (claims and/or description)
18.06.2018Despatch of a communication from the examining division (Time limit: M04)
20.09.2018Reply to a communication from the examining division
18.06.2019Communication of intention to grant the patent
23.10.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
23.10.2019Fee for grant paid
23.10.2019Fee for publishing/printing paid
04.12.2019Information about intention to grant a patent
04.12.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP11727401.9  / EP2582714
Opposition(s)16.10.2020No opposition filed within time limit [2020/52]
Fees paidRenewal fee
27.07.2015Renewal fee patent year 03
27.07.2015Renewal fee patent year 04
27.07.2015Renewal fee patent year 05
06.06.2016Renewal fee patent year 06
29.06.2017Renewal fee patent year 07
10.10.2018Renewal fee patent year 08
15.11.2019Renewal fee patent year 09
Penalty fee
Additional fee for renewal fee
30.06.201808   M06   Fee paid on   10.10.2018
30.06.201909   M06   Fee paid on   15.11.2019
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.06.2011
AL15.01.2020
AT15.01.2020
CY15.01.2020
CZ15.01.2020
DK15.01.2020
EE15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
MC15.01.2020
MK15.01.2020
MT15.01.2020
RO15.01.2020
RS15.01.2020
SE15.01.2020
SI15.01.2020
SK15.01.2020
SM15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
IE21.06.2020
LU21.06.2020
[2022/31]
Former [2022/30]HU21.06.2011
AL15.01.2020
AT15.01.2020
CY15.01.2020
CZ15.01.2020
DK15.01.2020
EE15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
MC15.01.2020
MT15.01.2020
RO15.01.2020
RS15.01.2020
SE15.01.2020
SI15.01.2020
SK15.01.2020
SM15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
IE21.06.2020
LU21.06.2020
Former [2022/28]HU21.06.2011
AT15.01.2020
CY15.01.2020
CZ15.01.2020
DK15.01.2020
EE15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
MC15.01.2020
MT15.01.2020
RO15.01.2020
RS15.01.2020
SE15.01.2020
SI15.01.2020
SK15.01.2020
SM15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
IE21.06.2020
LU21.06.2020
Former [2021/20]AT15.01.2020
CZ15.01.2020
DK15.01.2020
EE15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
MC15.01.2020
RO15.01.2020
RS15.01.2020
SE15.01.2020
SI15.01.2020
SK15.01.2020
SM15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
IE21.06.2020
LU21.06.2020
Former [2021/15]AT15.01.2020
CZ15.01.2020
DK15.01.2020
EE15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
MC15.01.2020
RO15.01.2020
RS15.01.2020
SE15.01.2020
SI15.01.2020
SK15.01.2020
SM15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
LU21.06.2020
Former [2021/11]AT15.01.2020
CZ15.01.2020
DK15.01.2020
EE15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
MC15.01.2020
RO15.01.2020
RS15.01.2020
SE15.01.2020
SI15.01.2020
SK15.01.2020
SM15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2020/50]CZ15.01.2020
DK15.01.2020
EE15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
RO15.01.2020
RS15.01.2020
SE15.01.2020
SK15.01.2020
SM15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2020/49]CZ15.01.2020
DK15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
RO15.01.2020
RS15.01.2020
SE15.01.2020
SK15.01.2020
SM15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2020/48]DK15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
RO15.01.2020
RS15.01.2020
SE15.01.2020
SM15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2020/47]DK15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
RS15.01.2020
SE15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2020/40]FI15.01.2020
HR15.01.2020
LV15.01.2020
RS15.01.2020
SE15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2020/39]FI15.01.2020
HR15.01.2020
LV15.01.2020
RS15.01.2020
SE15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
PT07.06.2020
Former [2020/38]FI15.01.2020
HR15.01.2020
LV15.01.2020
RS15.01.2020
SE15.01.2020
NO15.04.2020
GR16.04.2020
PT07.06.2020
Former [2020/37]FI15.01.2020
HR15.01.2020
LV15.01.2020
RS15.01.2020
SE15.01.2020
NO15.04.2020
PT07.06.2020
Former [2020/36]FI15.01.2020
RS15.01.2020
NO15.04.2020
PT07.06.2020
Former [2020/35]FI15.01.2020
NO15.04.2020
Documents cited:Search[A]WO2007031098  (XIGEN SA [CH], et al) [A] 1-15 * SEQ. ID. NO:1, 2, 9; p.22 *;
 [I]WO2009143865  (XIGEN SA [CH], et al) [I] 1-15 * Table 1; p. 11, l. 16; SEQ. ID. NO: 17, 39, 47 *;
 [A]  - BONNY C ET AL, "Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death", DIABETES, AMERICAN DIABETES ASSOCIATION, US, (20010101), vol. 50, no. 1, doi:10.2337/DIABETES.50.1.77, ISSN 0012-1797, pages 77 - 82, XP002172261 [A] 1-15 * abstract * * figure 1 *

DOI:   http://dx.doi.org/10.2337/diabetes.50.1.77
 [A]  - PAN JING ET AL, "Small peptide inhibitor of JNKs protects against MPTP-induced nigral dopaminergic injury via inhibiting the JNK-signaling pathway", LABORATORY INVESTIGATION, (201002), vol. 90, no. 2, ISSN 0023-6837, pages 156 - 167, XP002616484 [A] 1-15 * p. 157, col. 1, first par; abstract *

DOI:   http://dx.doi.org/10.1038/LABINVEST.2009.124
 [A]  - ROBINSON J A ET AL, "Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, (20050315), vol. 13, no. 6, doi:10.1016/J.BMC.2005.01.009, ISSN 0968-0896, pages 2055 - 2064, XP004759006 [A] 1-15 * Table 4a, compounds 1, 24-92; Fig. 1 *

DOI:   http://dx.doi.org/10.1016/j.bmc.2005.01.009
by applicantWO9705265
 US5674980
 US5804604
 WO2007031280
    - HUI ET AL., NATURE GENETICS, (200706), vol. 39, no. 6
    - ZHUANG ET AL., THE JOURNAL OF NEUROSCIENCE, (20060329), vol. 26, no. 13, pages 3551 - 3560
    - KUAN ET AL., CURRENT DRUG TARGETS - CNS & NEUROLOGICAL DISORDERS, (200502), vol. 4, no. 1, pages 63 - 67
    - GUENAT ET AL., J BIOMOL SCREEN, (2006), vol. 11, pages 1015 - 1026
    - GRANTHAM, R., SCIENCE, (1974), vol. 185, pages 862 - 864
    - KARLIN, PNAS USA, (1993), vol. 90, pages 5873 - 5877
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
    - ALTSCHUL ET AL., NUCLEIC ACIDS RES, (1997), vol. 25, pages 3389 - 3402
    - PEARSON, METHODS ENZYMOL., (1990), vol. 183, pages 63 - 98
    - PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. U. S. A, (1988), vol. 85, pages 2444 - 2448
    - DEVEREUX ET AL., NUCLEIC ACIDS RES., (1984), pages 387 - 395
    - SMITH; WATERMAN, J. MOL. BIOL., (1981), vol. 147, pages 195 - 197
    - ELLIOTT; O'HARE, CELL, (1997), vol. 88, pages 223 - 233
    - JACKSON, PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, pages 10691 - 10695
    - RUBEN, S. ET AL., J. VIROL., (1989), vol. 63, pages 1 - 8
    - HAUBER, J. ET AL., J. VIROL., (1989), vol. 63, pages 1181 - 1187
    - FRANKEL, A. D. ET AL., SCIENCE, (1988), vol. 240, pages 70 - 73
    - FRANKEL, A. D. ET AL., PROC. NATL. ACAD. SCI USA, (1988), vol. 85, pages 6297 - 6300
    - GARCIA, J. A., EMBO J., (1988), vol. 7, page 3143
    - SADAIE, M. R., J. VIROL., (1989), vol. 63, page 1
    - BACHMAIR, A. ET AL., CELL, (1989), vol. 56, pages 1019 - 1032
    - KAMEYAMA ET AL., BIOPO/YMERS, (2007), vol. 88, pages 98 - 107
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.